Femasys Inc. FEMY

Company Overview

Femasys Inc. is a U.S.-based biomedical company focused on women’s health, with a primary emphasis on infertility, reproductive medicine, and minimally invasive gynecologic solutions. The company develops and commercializes diagnostic and therapeutic products intended for office-based use by healthcare providers. Femasys operates within the medical device and women’s healthcare industries, targeting unmet needs in fertility treatment and reproductive health management. Its core revenue drivers include infertility diagnostics, fallopian tube assessment technologies, and emerging reproductive intervention products designed to reduce reliance on more invasive or costly procedures.

The company’s principal commercial products include FemaSeed, an intratubal insemination product for infertility treatment, and FemVue, a saline-air contrast sonography system used to evaluate fallopian tube patency. Femasys also develops investigational and pipeline products such as FemBloc, a non-surgical permanent birth control candidate, and other reproductive health technologies. Founded in 2004 and headquartered in Georgia, the company evolved from a development-stage medical technology enterprise into a publicly traded commercial-stage company listed on Nasdaq under the ticker FEMY. Its strategic positioning centers on offering office-based alternatives to surgical or resource-intensive fertility and gynecologic procedures.

Business Operations

Femasys generates revenue primarily through the sale of women’s health medical devices and related consumables to fertility clinics, obstetricians, gynecologists, and reproductive medicine specialists. The company’s operations are concentrated around proprietary reproductive healthcare technologies that support infertility diagnosis and treatment. Its commercial infrastructure focuses mainly on the United States, although the company has pursued international commercialization opportunities through distribution arrangements and regulatory initiatives in selected foreign markets.

The company controls a portfolio of patented technologies and product platforms related to intrauterine and intratubal access, reproductive imaging, and minimally invasive gynecologic intervention. Key operating assets include the commercialized FemVue and FemaSeed systems as well as investigational programs such as FemBloc. Femasys has historically relied on collaborations with clinical investigators, fertility specialists, and distribution partners to support product adoption and clinical validation. Public disclosures identify intellectual property protection and regulatory expertise as important operational components supporting commercialization and product development activities.

Strategic Position & Investments

Femasys’ strategic direction is centered on expanding its presence in reproductive medicine through commercialization of minimally invasive, office-based technologies that address infertility and permanent contraception. The company has invested significantly in clinical development, regulatory approvals, physician education, and commercialization infrastructure for products such as FemaSeed and FemBloc. Management has emphasized the potential cost and accessibility advantages of office-based reproductive procedures compared with traditional surgical or assisted reproductive interventions.

The company’s investment priorities include advancing clinical studies, strengthening intellectual property protections, and broadening market adoption among fertility specialists and women’s health providers. Femasys is also involved in emerging areas of reproductive intervention technology focused on reducing procedural complexity and improving patient access. Public filings and investor materials identify continued regulatory advancement and commercial scale-up as central growth initiatives. Data regarding material acquisitions or large-scale portfolio holdings is limited in publicly available disclosures, and no major diversified subsidiary structure has been prominently reported.

Geographic Footprint

Femasys is headquartered in Atlanta, Georgia, and its principal operational and commercial activities are concentrated in the United States. The company primarily serves U.S.-based fertility clinics, reproductive endocrinologists, and obstetrics and gynecology practices. Its commercialization strategy has focused on expanding physician adoption across domestic reproductive healthcare markets, particularly in office-based infertility diagnostics and treatment settings.

Internationally, Femasys has pursued selective market opportunities through regulatory clearances, distribution partnerships, and exploratory commercialization efforts. Public disclosures reference activities in regions outside the United States, including parts of Europe and other international healthcare markets, although the company’s primary revenue base remains domestic. Its broader international influence is currently tied more to intellectual property, clinical engagement, and product registration efforts than to large-scale overseas operations.

Leadership & Governance

Femasys was founded by Kathy Lee-Sepsick, who has played a central role in shaping the company’s strategic direction toward minimally invasive reproductive healthcare technologies. Leadership has consistently emphasized innovation in women’s health, physician office efficiency, and expanding patient access to fertility and reproductive solutions. Governance and operational oversight are conducted through a combination of executive leadership and an independent board structure consistent with Nasdaq-listed public companies.

Key executives and leadership figures include:

• Kathy Lee-Sepsick – Founder, President, Chief Executive Officer, and Chairman
• Michael Pauls – Chief Financial Officer
• Mark T. Eid – Chief Commercial Officer
• Richard Spector, M.D. – Chief Medical Officer

The company’s leadership philosophy, as reflected in public filings and corporate communications, focuses on addressing unmet clinical needs in women’s healthcare through innovation, evidence-based product development, and scalable office-based treatment solutions.